Crispr Therapeutics AG Market Cap ($5.23 Billion)
Market Cap & Net Worth: Crispr Therapeutics AG (CRSP)
Crispr Therapeutics AG market cap. Crispr Therapeutics AG (NASDAQ:CRSP) has a market capitalization of $5.23 Billion ($5.23 Billion) as of October 31, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #3378 globally and #1210 in its home market, demonstrating a 7.45% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Crispr Therapeutics AG's stock price $54.26 by its total outstanding shares 96448792 (96.45 Million).
Crispr Therapeutics AG Market Cap History (2016–2026)
Crispr Therapeutics AG market cap history from 2016 to 2026. Data shows growth from $1.95 Billion to $5.23 Billion (14.38% CAGR). Check today's stock price for Crispr Therapeutics AG for real-time trading data and today's change.
Index Memberships
Crispr Therapeutics AG is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.20% | #87 of 976 |
|
NASDAQ Composite
IXIC
|
$40.85 Trillion | 0.01% | #386 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.28% | #59 of 263 |
Weight: Crispr Therapeutics AG's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Crispr Therapeutics AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Crispr Therapeutics AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see CRSP cash flow conversion for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
1440.96x
Crispr Therapeutics AG's market cap is 1440.96 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.95 Billion | $5.16 Million | -$23.20 Million | 378.40x | N/A |
| 2017 | $2.26 Billion | $41.00 Million | -$68.36 Million | 55.24x | N/A |
| 2018 | $2.76 Billion | $3.12 Million | -$164.98 Million | 882.06x | N/A |
| 2019 | $5.87 Billion | $289.59 Million | $66.86 Million | 20.28x | 87.86x |
| 2020 | $14.77 Billion | $719.00K | -$348.87 Million | 20538.63x | N/A |
| 2021 | $7.31 Billion | $913.08 Million | $377.66 Million | 8.00x | 19.35x |
| 2022 | $3.92 Billion | $436.00K | -$650.17 Million | 8992.30x | N/A |
| 2023 | $6.04 Billion | $370.00 Million | -$153.61 Million | 16.32x | N/A |
| 2024 | $3.80 Billion | $35.00 Million | -$366.25 Million | 108.46x | N/A |
| 2025 | $5.06 Billion | $3.51 Million | -$581.60 Million | 1440.96x | N/A |
Competitor Companies of CRSP by Market Capitalization
Companies near Crispr Therapeutics AG in the global market cap rankings as of October 31, 2026. See CRSP equity financing ratio to understand what proportion of total assets are financed by equity.
Key companies related to Crispr Therapeutics AG by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #183 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #374 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #422 globally with a market cap of $67.80 Billion USD ( AU$95.82 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #498 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #183 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $540.00 |
| #374 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $818.77 |
| #422 | CSL Ltd | AU:CSL | $67.80 Billion | AU$197.50 |
| #498 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $222.76 |
Market Capitalization of Crispr Therapeutics AG (2016–2026)
Market capitalization of Crispr Therapeutics AG from 2016 to today. Between 2016 and today, Crispr Therapeutics AG's market cap moved from $1.95 Billion to $ 5.23 Billion, with a yearly change of 14.38%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $5.23 Billion | +3.47% |
| 2025 | $5.06 Billion | +33.23% |
| 2024 | $3.80 Billion | -37.12% |
| 2023 | $6.04 Billion | +54.00% |
| 2022 | $3.92 Billion | -46.36% |
| 2021 | $7.31 Billion | -50.51% |
| 2020 | $14.77 Billion | +151.39% |
| 2019 | $5.87 Billion | +113.18% |
| 2018 | $2.76 Billion | +21.68% |
| 2017 | $2.26 Billion | +15.89% |
| 2016 | $1.95 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 30th, 2026 the market cap of Crispr Therapeutics AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.23 Billion USD |
| MoneyControl | $5.23 Billion USD |
| MarketWatch | $5.23 Billion USD |
| marketcap.company | $5.23 Billion USD |
| Reuters | $5.23 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Crispr Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of … Read more